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Embedded Chitosan Sponge for
Topical and Local Administration
of Chemotherapeutic Agents
The following work describes the development of a novel noninvasive transmucosal drug
delivery system, the chitosan sponge matrix (CSM). It is composed of cationic chitosan
(CS) nanoparticles (NPs) that encapsulate cisplatin (CDDP) embedded within a poly-
meric mucoadhesive CS matrix. CSM is designed to swell up when exposed to moisture,
facilitating release of the NPs via diffusion across the matrix. CSM is intended to be
administered topically and locally to mucosal tissues, with its initial indication being
oral cancer (OC). Currently, intravenous (IV) administered CDDP is the gold standard
chemotherapeutic agent used in the treatment of OC. However, its clinical use has been
limited by its renal and hemotoxicity profile. We aim to locally administer CDDP via
encapsulation in CS NPs and deliver them directly to the oral cavity with CSM. It is
hypothesized that such a delivery device will greatly reduce any systemic toxicity and
increase antitumor efficacy. This paper describes the methods for developing CSM and
maintaining the integrity of CDDP NPs embedded in the CSM.
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1 Introduction
There is a growing demand for safer, more effective routes of
drug delivery. Two major methods, NP encapsulation and buccal
administration, have been gathering a large amount of attention as
alternatives to the more traditional oral and IV routes. Buccal
delivery has been widely used in various forms, including gels
[1], films [2], and tablets [3] to deliver vitamins [4], peptides [5],
or antibiotics [6]. On the other hand, NP formulations have been
used for targeted systemic delivery of agents [7]. CS, a natural
cationic polysaccharide comprised of the copolymers N-acetyl
glucosamine and glucosamine [8] has been widely utilized in such
systems. It is produced via the deacetylation of chitin (Fig. 1), a
structural polymer found in the shells of crustaceans [9] and
widely considered to be among the most useful polymers in phar-
maceutical research due to its abundance, biodegradability, and
biocompatibility [10].
Localized buccal and NP delivery routes would be most suited in
applications utilizing drugs with dose-limiting toxicities and severe
side effects, such as chemotherapeutics. There is published literature
regarding buccal and topical NP systems to administer chemother-
apy agents such as 5-fluoruracil [11,12]. However, there are no
reports of NPs physically incorporated within a buccal device. Con-
sequently, this paper will discuss the development of a novel drug
delivery system, the CSM (Fig. 2). CSM is composed of CS NPs
encapsulating CDDP embedded within a polymeric CS matrix.
CSM is intended for topical and local administration directly onto
the tumor to reduce the toxic side effects of chemotherapy. Its initial
indication is OC; however, it is a platform technology that can be
used to treat other cancers such as melanoma.
There is a significant unmet need in the treatment of OC.
Unlike other cancers, the incidence of OC is on the rise in the
U.S. primarily due to increasing rates of human papillomavirus-16
infection [13]. It is estimated that over 42,000 people in the U.S.
and over 640,000 people worldwide were diagnosed with OC in
2014 [14]. Its five year relative survival rate remains at a mere
62.7% [14]. Despite this, there has been little progress in the de-
velopment of innovative translational therapies for OC to both
improve efficacy and reduce unwanted side effects. The current
gold standard of care for OC is an IV CDDP infusion combined
with radiotherapy and surgery [15]. Depending on the patient and
condition, these infusions may be administered over a period
ranging from weeks to months, with each treatment lasting several
hours. For instance, patients with stage III locally advanced oral
tumors will receive one 40–50 mg/m2 IV of CDDP daily for 6–7
weeks with concurrent radiation [16].
CDDP ((SP-4-2)-diamminedichloroplatinum (II)) is an alkyl-
ating agent that has been used in the treatment of a wide assort-
ment of cancers [17–19]. First Food and Drug Administration
(FDA) approved in 1978, CDDP remains the most effective
choice of platinum-based chemotherapeutics. Its mechanism of
action first involves CDDP entering the cell via both active and
passive transport [20,21]. Upon entering the nucleus, CDDP loses
its two chlorine atoms and binds to the nitrogen atoms of two con-
secutive purine bases on the deoxyribonucleic acid (DNA), form-
ing CDDP-DNA cross-linked adducts. These adducts cause a
conformational change in the DNA, allowing for the binding of
high mobility group domain proteins. Once bound, high mobility
group proteins destabilize the base pairs beyond reparation, halt-
ing DNA transcription and replication, ultimately inducing apo-
ptosis [22]. Despite its proven efficacy when dosed properly, the
dosing options of IV CDDP in patients are often limited to subop-
timal treatment levels due to systemic toxicity and severe side
effects. These side effects include nausea and vomiting, anemia,
mucositis, ototoxicity, neurotoxicity, and nephrotoxicity [23,24].
Additionally, once in the bloodstream CDDP faces two significant
issues: (a) CDDP is subject to chemical deactivation by substitu-
tion or elimination of amine groups [25], and (b) being a nontar-
geted molecule, only a fraction of CDDP actually reaches the
tumor site. This can be attributed to the small size of CDDP mole-
cules, which allows them to easily diffuse through a tumor’s mal-
formed and permeable vasculature [26] rather than remain local.
To address the aforementioned issues of IV CDDP, we have
encapsulated CDDP within CS NPs and embedded them within
CSM (Fig. 2) intended for topical and local application to OC
tumors. Encapsulation of CDDP protects it from biological deacti-
vation and promotes increased rates of cell uptake [27]. Addition-
ally, using cationic CS as the polymer for both the NPs and CSM
allows for electrostatic interactions between it and anionic
domains of mucin proteins in the oral cavity. This mucoadhesive
property is what allows the NPs, and subsequently CDDP, to
remain local to the delivery sites.
The CSM is able to preserve NPs in a stable environment and
promote passage across epithelial barriers. It is designed with an
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impermeable ethylcellulose backing to provide unidirectional
drug delivery and prevent CDDP NP washout from saliva (Fig. 2).
When hydrated with a wetting agent such as saline, CSM swells
up and transforms to a mucoadhesive hydrogel, covering the tu-
mor and allowing the NPs to diffuse across the porous matrix into
the tumor tissue. Properties including NP size and surface charge
can be controlled to allow for an even greater degree of targeting
depending on the severity and size of the tumor. Several in vitro
tests studying the release of CDDP from the NPs and NP cell
uptake will be discussed in this paper. Based on what has been
discussed above, it can be hypothesized that polymeric CS NPs
can be embedded within CSM without damaging the structural
integrity of the NPs or the sponge.
2 Materials and Methods
2.1 Materials and Equipment. All the chemicals and
equipment were obtained from commercial suppliers. The list of
chemicals is shown in Table 1 and they were used as received. All
water-based solutions were prepared with double deionized water.
2.1.1 Materials. Hamster cheek pouch carcinoma cells
(HCPC-1), human pharyngeal squamous cell carcinoma cells
(FaDu), and buccal epithelial TR146 cells were used for the
in vitro and in vivo studies.
2.1.2 Equipment. Malvern ZetaSizer Nano ZS90 was used for
measuring the size, polydispersity (PDI), and the polydistribution
index. Malvern NanoSight was used for detecting NPs released
from the CSM in human saliva. 30k Pall NanoSep centrifugal fil-
ters were used for filtration, separation, and purification of the
NPs. Inductively coupled plasma atomic emission spectroscopy
(ICP-AES) was used for detecting any traces of CDDP.
2.2 Preparation of Cisplatin Nanoparticles (CDDP
NPs). Several optimization studies were performed by altering the
mass ratio of CS to tripolyphosphate (TPP) and synthesis pH to
determine a formulation that yielded NPs of desirable size and
charge, with low PDI and high encapsulation efficiency. CDDP
NPs were synthesized via the proven ionic gelation technique
[28]. CDDP (1.5 mg/mL) was added to deionized (DI) water and
the mixture was sonicated for 4 hrs until CDDP was completely
dissolved. A 0.175% v/v acetic acid solution was prepared from
100% glacial acetic acid. CS Cl113 (1.0 mg/mL) was dissolved in
this solution on a vortex for 10 mins. The CS solution was trans-
ferred to a beaker under magnetic stirring (600 rpm). TPP was
Fig. 2 Schematic diagrams of the CSM. CSM can be molded to have several sizes, however
the current size of 1.53 1.5 cm2 provides adequate coverage of a tumor that is 1 cm in diame-
ter. The sponge is 2 mm in height. Note that the backing ethyl cellulose can be brushed on the
back of CSM to create a unidirectional application. The CSM is designed to remain on the
tumor for 1 hr and the remaining CSM with its non degradable ethylcellulose backing will be
discarded (a). CS (CDDP NPs) (b). Ex vivo study: CSM is placed on the freshly harvested
lamb’s tongue for permeation studies. Transition of the CSM into a hydrogel after 5 mins of
exposure to a wetting agent (c).
Fig. 1 Molecular structures and formation conditions for chitin and CS. The acetyl groups (C2H3O) are removed from chitin to
form CS. Note how the CS primary amine groups (NH2) become protonated in acidic conditions.
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then added to the CDDP solution (0.45 mg/mL) and vortexed for
1 min until completely dissolved. Immediately after, the CDDP-
TPP solution was added dropwise at a flow rate of 1 mL/min,
resulting in a final volume ratio of 1.1 mL CS:0.85 mL CDDP-
TPP. The solutions were left to mix for 15 mins prior to
characterization.
2.2.1 Preparation of Blank Nanoparticles. Blank nanopar-
ticles (BLK NPs) were synthesized employing ionic gelation [28].
TPP was dissolved in water (1.0 mg/mL) and filtered through a
0.22lm syringe filter. A 0.175% v/v acetic acid solution was pre-
pared from 100% glacial acetic acid. CS Cl113 (1.0 mg/mL) was
dissolved in this solution on a vortex for 10 mins. The CS solution
was transferred to a beaker under magnetic stirring (600 rpm).
TPP solution was added dropwise from a pipette at a flow rate of
1 mL/min, resulting in a final volume ratio of 1.0 mL CS:0.25 mL
TPP. The solutions were left to mix for 15 mins prior to
characterization.
2.2.2 Preparation of Fluorescent Labeled CS NPs. Fluorescein
isothiocyanate salt-chitosan and Alexa Fluor 647-chitosan NPs
(FITC-CS NPs and ALX-CS NPs) were synthesized in order to
detect the NPs in permeation, release and cell uptake studies. Prior
to NP preparation, CS Cl113 was hydrated in 0.175% v/v acetic
acid (1.0 mg/mL). The solution was left to stir in a beaker for 1 hr
at 500 rpm and the pH was adjusted to 6.0 with 0.1 M NaOH.
FITC was dissolved in 100% ethanol (10 mg/mL). FITC solution
was added to the CS Cl113 solution dropwise to achieve a final
concentration of 0.04 mg/mL. 1-ethyl-3-(3-dimethylaminopropyl)
carbodiimide (EDC) salt was added to the solution (0.84 mg/mL)
and the mixture allowed to stir for 12 hrs and then dialyzed for
two days (Fig. 3). The purified solution was frozen on dry ice and
lyophilized for 72 hrs at 50 mTorr and 90 C. The ionic gelation
method was used to synthesize the FITC-CS NPs [28].
Lyophilized FITC-CS was rehydrated in 0.175% v/v acetic acid
(1.0 mg/mL) and stirred overnight at 200 rpm. TPP was dissolved
in water (1.0 mg/mL) and was added dropwise to the FITC-CS
solution under magnetic stirring (600 rpm) at a flow rate of 1 mL/
min. The final volume ratio of the solutions was 1.0 mL FITC-
CS:0.5 mL TPP. The NP solution stirred for 15 mins prior to
characterization. The same preparation was used for ALX-CS
NPs, with a simple substitution of ALX for FITC.
2.2.3 Characterization of CS NPs
2.2.3.1 Dynamic Light Scattering (DLS). 1.0 mL and 800ll
of each NP solution were placed in a separate polystyrene cuvette
and zeta potential cell, respectively. Measurements were taken
using a ZetaSizer Nano (Malvern) to determine the size, charge,
and PDI of the NPs. Backscatter detection was employed at an
angle of 173 deg.
2.2.3.2 Encapsulation Efficiency (EE). The CDDP NP solu-
tion was transferred to a 30 k Pall NanoSep centrifugal filter and
centrifuged for 8 mins at 1100 relative centrifugal force (RCF).
The NPs encapsulating CDDP remained in the top compartment
while free CDDP was in the bottom of the tube. The NPs were
washed with 0.175% acetic acid to remove any CDDP stuck to the
surface of the NPs and were subsequently centrifuged again
(repeated 3). The top and bottom compartments were analyzed
for platinum (Pt) concentration with ICP-AES. Encapsulation effi-
ciency was determined using the following equations:
Total CDDP in Solution 0:648% ¼ Initial Pt amount mgð Þ
(1)
Volume of NP in top compartment mLð Þ  Pt concentration
mg=mLð Þ ¼ Amount of Pt Encapsulated mgð Þ (2)
Volume of free CDDP solution in bottom compartment mLð Þ
 Pt concentration mg=mLð Þ ¼ Amount of free Pt mgð Þ
(3)
EE% ¼ Amount of Pt encapsulated mgð Þ=
Initial Pt amount mgð Þ  100% (4)
2.2.4 In Vitro MTS (Colorimetric) Cytotoxicity Assay
(CDDP NPs). HCPC-1 and FaDu cells were each cultured in with
Dulbecco’s modified Eagle’s medium and 10% fetal bovine serum
until a minimum density of 2 105 cells/mL was reached. Cells
Table 1 List of chemical and materials
Type Molecular weight Property Manufacturer
CS chloride salt Cl113 (CS Cl113) 50–150 kDa Deacetylation degree 75–90% Novamatrix, FMC BioPolymer
CS glutamate G113 (CS G113) 50–150 kDa Deacetylation degree 75–90% Novamatrix, FMC BioPolymer
CDDP H6Cl2N2Pt 300 g/mol Chemotherapy agent Strem Chemicals
Sodium TPP Na5P3O10 367.864 g/mol Cross-linker used for ionic gelation Sigma-Aldrich
Glacial acetic acid C2H4O2 60.05 g/mol Solvent for CS Sigma-Aldrich
MTS cytotoxicity assay — Cell viability assay BioVision
FITC C21H11NO5S 389.4 g/mol Fluorescent labeling can be conjugated to CS Life Technologies
ALX 594 nm or 633 nm laser Fluorescent labeling can be conjugated to CS Life Technologies
Sodium hydroxide (NaOH) 39.99 g/mol Used for adjusting pH levels Sigma-Aldrich
Fig. 3 Molecular structures of FITC, CS, and FITC-CS. FITC-CS is synthesis is catalyzed by the addition of EDC. The primary
amine of CS acts as a nucleophile to the carboxylic acid of FITC and forms a covalent bond between the two molecules. The
secondary amine on FITC-CS is unable to become protonated and will remain neutral.
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were transferred to a 96-well microtiter plate. The well known cyto-
toxicity assay, MTS reagent was added according to the manufac-
turer’s protocol. BLK NPs, CDDP NPs, and free CDDP were
added to each well in varying concentrations and allowed to incu-
bate for 48 hrs. Cell viability percentage was determined by the
reagent’s color intensity according to the manufacturer’s guide-
lines. Color intensity was quantified by a plate reader.
2.2.5 In Vitro Cell Uptake Study. Cultured TR146 cells
(human buccal squamous cell carcinoma) were separately incu-
bated with ALX NPs (0.03 g/L) for periods of both 30 and
60 mins. Cells were analyzed using fluorescence-activated cell
sorting (FACS) and percentage cell uptake was determined. Note:
It was determined that utilizing both human oral buccal (TR146)
and human oral pharyngeal (FaDu) cell lines would better repre-
sent he complex environment of the mouth.
2.2.6 CDDP NP Drug Release Study. CDDP NPs were syn-
thesized via ionic gelation as described above. The particles were
then characterized with DLS for size and surface charge. NPs
were washed with 0.175% acetic acid to remove any free CDDP
on the surface. They were then purified via centrifugation (1100
RCF, 8 mins) in a 30k molecular weight cutoff (MWCO) PALL
centrifuge filter. NPs were placed in a dialysis bag within a beaker
of phosphate buffered saline (PBS) buffer (pH 7.2) to simulate
salivary fluids. Samples were drawn at varying time points and an-
alyzed for CDDP content using ICP-AES to calculate the release
profile
%Release ¼ Amount of CDDP in sample mgð Þ=
Amount of CDDP in filtered NPs mgð Þ  100%
(5)
2.3 Synthesis of CSM. CS G113 was dissolved in a 1.0% v/v
aqueous acetic acid solution (17.0 mg/mL) under magnetic stirring
for 1 hr at 700 rpm. CDDP NP, BLK NP, or 1 mg/mL CS Cl113)
solution was combined with the CS G113 solution in a ratio of
10.0 mL:1.0 mL. This was frozen in liquid nitrogen for 25 mins
and lyophilized for two days.
2.3.1 Stability of NPs in CSM Solution. Freshly synthesized
NP solution (CDDP, ALX, FITC, and BLK) was combined with
the CSM sponge solution in varying v/v aqueous ratios (1.1:0.85,
1.1:0.8, 1.1:0.5, 1.1:0.4, 1.1:0.45, and 1.1:0.30) of CDDP
NP:CSM. The size, charge, and PDI of the NPs were measured
using DLS.
2.3.2 Integrity of NPs in Lyophilized CSM. CSMs were placed
in human saliva and the released fluorescent NPs were visualized
and quantified with NanoSight (Malvern). Note: Malvern Nano-
Sight utilizes nanoparticle tracking analysis to characterize and
analyze each NP individually. It allows for the detection of NPs
even in solutions containing polymers and proteins.
2.3.3 Scanning Electron Microscopy (SEM). CSMs were
placed under a Denton-Vacuum Desk IV sputter coater and
sprayed with a 10 nm thick layer of gold–palladium alloy. Sam-
ples were then mounted and imaged inside a JEOL 7401F field
emission scanning electron microscope.
3 Results and Discussion
3.1 Synthesis of CS NPs. Results of CDDP NP syntheses are
described in Table 2. It was observed that increasing the CS solu-
tion concentration while keeping TPP constant (1 mg/mL) yielded
CDDP NPs with a larger size and zeta potential (Figs. 4(a) and
4(b)). In contrast, as the TPP concentration was increased and CS
kept constant (1 mg/mL) it lowered the surface charge of the
CDDP NPs (Fig. 4(c)). There was no observable trend between
NP size and the modulation of TPP concentration (Fig. 4(d)).
Upon increasing the pH, the zeta potential and size of the NPs
both increased (Figs. 4(e) and 4(f)). CDDP NPs displayed a high
encapsulation efficiency of 78%. Two fluorescent variants of CS
NPs displayed lower zeta potential and larger size and were
functional when observed under their respective excitation wave-
lengths (495 nm and 647 nm).
We found that NP parameters such as size and charge were able
to be modulated by altering the concentration of reagents and pH
of the synthesis procedure. The functional portion of CS mole-
cules is a primary amine group, which becomes protonated in
acidic conditions (pKa¼ 6.5), endowing CS with cationic proper-
ties. We hypothesize that the larger size and zeta potential
observed with increasing CS concentration can be attributed to the
higher abundance of amine groups. The more positive charges
present, the stronger the repulsive forces are between CS chains,
increasing their intermolecular distance, thus the size of NPs. The
reduced charge seen when increasing the concentration of TPP is
due to the higher amount of TPP anions counteracting the cationic
amine groups, effectively neutralizing their charge. Additionally,
the observed negligible impact of TPP concentration on NP size
suggests that the amount of cross-linking anions do not play a sig-
nificant role in determining the size of the NPs. Increasing the pH
of the CS solution prior to synthesis lowers the degree of amine
protonation. This limits the number of potential cross-linking sites
available for TPP anions to interact with while forming NPs. This
lower cross-linking density leads to larger NPs, and the smaller
amount of amine groups yields a lower overall positive charge.
However, there is a slight deviation in the overall trends of
increasing the CS concentration and TPP concentration. The spike
in size at 1.25 mg/mL CS concentration (Fig. 4(d)) and 0.7 mg/mL
TPP concentration (Fig. 4(b)) can be attributed to the close mass
ratios of CS to TPP in both instances (5.00:1.00 and 5.71:1.00,
respectively). This suggests a critical point is reached at these pro-
portions where larger NPs are formed than usual and more studies
will be conducted to investigate this phenomenon.
We hypothesize that the decreased zeta potential and increased
size seen on both the FITC and ALX CS NPs are due to the fluoro-
phore conjugation site being the amine group of CS. This reaction
reduces the zeta potential because it transforms the primary amine
into a secondary amine, eliminating its ability to become proto-
nated and thus decreases its cationic potential. However, it should
be noted that this reaction does not substitute every amine group,
and the unreacted primary amines are what give the ALX/FITC-
CS NPs a remaining degree of positive charge. We believe the
increased size of the fluorescent NPs is due to both the reduction
of TPP cross-linking sites and the increased steric hindrance of
the large fluorescent molecule conjugates. (Fig. 3).
The optimal mass ratio for blank/fluorescent NPs was 4.0
CS:1.0 TPP and 2.88 CS:1.0 TPP for CDDP-CS NPs. These were
Table 2 The average properties observed for different types of CS NPs synthesized as described in text
NP type Avg. size (nm) (Std. Dev.) Avg. charge (mV) (Std. Dev.) Avg. PDI (Std. Dev.)
Blank NP 122.97 (7.13) þ35.2 (3.45) 0.29 (0.01)
CDDP NP 70.46 (7.21) þ 31.4 (2.78) 0.20 (0.02)
ALX NP 185.27 (105.87) þ16.9 (3.76) 0.34 (0.10)
FITC NP 143.3 (25.67) þ19.3 (1.14) 0.13 (0.03)
Note: Values derived from DLS measurements. Each type of NP was synthesized a minimum of three times to ensure accuracy and reproducibility.
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determined based on the proportions of CS to TPP that produced
the smallest size, highest zeta potential, and lowest PDI for each
formulation. Ultimately, the best combination for CDDP NPs
yielded small NPs (<100 nm), a positive zeta potential
(20–30 mV), and low PDI (<0.20). For the treatment of OC, these
properties are ideal. A low PDI index indicates that the size distri-
bution of the NPs is narrow, which is important for therapeutic ef-
ficacy. According to published literature, particles of this size
range pass through the 50 cell layer thick oral epithelium [29] and
reach the basement membrane where cancerous stem cells may re-
side [30]. The positive charge is critical to ensure that the NPs
remain local and rapidly taken up by cells [27]. We observed that
if the CDDP-TPP solution was not used immediately, its pH
begins to decrease within 15 mins and such time gaps can alter the
NP characteristics between batches. Based on our data: (1) The
properties of CS-TPP NPs can be easily modulated by varying the
mass ratio of CS to TPP and (2) CS concentration plays a greater
role in altering the size and surface charge of NPs than TPP.
3.2 Stability of CDDP-TPP Solution. Throughout the course
of the NP synthesis procedure, the pH of all solutions was moni-
tored for variation. We observed that the pH of the freshly synthe-
sized CDDP solution pH was 4.25 (60.07). This varied
significantly from the pH of the DI water it was prepared in
(5.546 0.11, stored in an airtight container at 25 C). Immediately
after addition of TPP to the solution, the pH increased to 6.81
(60.08) and proceeded to decrease linearly over the course of
9 hrs to 6.17 (60.09) (Fig. 5(a)). The rate of this decrease was
affected by the pH of the CDDP solution (adjusted with 0.1 M
NaOH), with higher pH’s corresponding to faster rates of pH
depression (Fig. 5(b)). Additionally, it was observed that after
72 hrs at room temperature unprotected from light the CDDP-TPP
solution formed a blue precipitate. This did not occur when it was
stored in a light-blocking container.
We hypothesize that the decrease in pH is due to the hydrolysis
of CDDP [31]. The chloride ions of CDDP are excellent
leaving groups and are readily replaced by water ligands after
Fig. 4 (a) Effect of increasing the TPP concentration on NP zeta potential. CS concentration
was kept constant at 1.0 mg/mL (b) impact of increasing TPP concentration on NP size. CS
concentration was kept constant at 1.0 mg/mL (c) results of increasing CS concentration on
NP zeta potential. TPP concentration remained at 1.0 mg/mL (d) effect of increasing CS con-
centration on NP size. TPP concentration was fixed at 1.0 mg/mL (e) impact of increasing the
CS solution pH used for NP synthesis with 0.1 M NaOH (f) results of increasing the CS solution
pH used for NP synthesis with 0.1 M NaOH. When the TPP concentration was increased, there
was a clear trend in the reduction of NP zeta potential, but no predictable impact was made on
NP size. The zeta potential and size both increased when the CS concentration was height-
ened. The NPs produced with higher pH CS solutions showed both larger size and lower zeta
potential.
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dissolution [31]. This reaction results in the formation of posi-
tively charged mono or di aqueous CDDP species [31], and we
hypothesize that free hydrochloric acid (HCl) is formed as a
byproduct, lowering the pH of the solution. Hydrolysis of CDDP
can be slowed by the addition of excess chloride ions to the sys-
tem to create an equilibrium between free Cl and Cl on CDDP
[32]. Even if CDDP becomes hydrolyzed, the mono and di aque-
ous Pt species are therapeutically potent [33,34] and can still be
encapsulated in CS NPs for treatment. We plan on investigating
the impacts of adding Cl in the form of NaCl on the NP synthesis
process and evaluating the presence of CDDP and its hydrolyzed
species via high-performance liquid chromatography (HPLC).
In addition to the reactivity of CDDP with water, CDDP can
also react with phosphate-based compounds such as TPP [35]. We
believe one of the byproducts of these reactions is phosphoric acid
(PO4
), which is responsible for subsequent decline in pH seen
when TPP is added to the CDDP solution. We also found these
reactions to pH dependent (Figs. 5(a) and 5(b)). When CDDP-
TPP solution pH was raised with 0.1 M NaOH, the rate of pH
decline was more rapid compared to the unadjusted control. This
suggests that a higher abundance of reactive deprotonated
oxygens on TPP react with CDDP more quickly to produce of
PO4
 in greater quantities. Because of these reactions, the NPs
and CSM must be thoroughly characterized at each step of the
synthesis process to identify and quantify the presence of CDDP-
phosphato derivatives. Additionally, the blue precipitate observed
is a dinuclear phosphate-platinum complex [35] formed by the
bonding of two phosphate-platinum complexes. This formed more
rapidly CDDP when TPP was exposed to light, inferring that light
plays a key role in the catalytic formation of this product.
In conclusion, the mixing of TPP with the CDDP solution is a
critical parameter to control during NP synthesis. Once made, the
solution should be used immediately to minimize batch to batch
variability caused by the changing pH and production of CDDP-
TPP compounds. We will develop a method to identify and
quantify the potential CDDP derivatives formed in our synthesis
procedure and discuss the findings in our next publication. It is
imperative that a translational product like CSM is thoroughly an-
alyzed in order to meet the FDA’s stringent characterization
requirements for active drug substances.
3.3 In Vitro MTS Cytotoxicity Assay and Cell Uptake
Study. As shown in Fig. 6, HCPC-1 cells treated with CDDP
NPs, free CDDP, and BLK NPs showed 23%, 38%, and 68% cell
viability, respectively. Also shown is the viability of FaDu cells
treated with CDDP NPs, free CDDP, and BLK NPs showed corre-
sponding values of 21%, 49%, and 87%. Figure 7 illustrates that
after 30 mins of incubation, 98% of TR-146 cells were positive
for ALX CS NPs and in 60 mins, 95% of cells were positive for
ALX CS NPs. No fluorescence was detected in the TR-146 control
cells.
We postulate that the variability seen in the cell uptake percent-
age versus time is due to the slight degradation of NPs in the cell
culture medium; however, a difference of only 3% is negligible
and can also be attributed to the natural variability of an in vitro
experiment with live cells. The lower viability observed in the
CDDP NP group is due to the NPs having a high rate of cell
uptake (Fig. 7) via direct membrane translocation (DMT) [27].
This energy-autonomous mechanism is facilitated by the cationic
surface charge of NPs due to protonated amine groups. Although
DMT is not fully understood, it is known that this path provides a
rapid rate of uptake without harming the membrane or causing cy-
totoxicity [27]. Higher uptake efficiency contributes to a proficient
destruction of cancerous cells and minimizes the potential for
mutations to develop via cell proliferation, creating genomic het-
erogeneity [36]. The greater efficacy of CDDP NPs observed in
these experiments compared to free CDDP is due to the encapsu-
lation within NPs, which provides swift uptake via DMT and pro-
tection from chemical deactivation. It is important to note that the
decreased cell viability seen for BLK NPs can be attributed to the
natural anticancer properties of CS [37]. CS or CS NPs exhibit
virtually no cytotoxicity in noncancerous cell lines [38].
3.4 CDDP NP Release Study. In order to be therapeutically
efficacious, CDDP NPs must release their payload in a manner
which destroys cancer cells as rapidly as possible. Figure 8 illus-
trates the bolus release profile observed with the CDDP NPs in pH
7.2 PBS. Eighty percentage of CDDP was released within the first
5 hrs, with 100% release seen at 50 hrs. Release of CDDP is cata-
lyzed by the swelling of the NPs at pH 7.2. A neutral pH causes
the deprotonation of amine groups on CS and their subsequent
loss of a net positive charge (NHþ3 ! NH2). This loss inhibits the
electrostatic interactions with TPP and lowers the NPs cross-
linking density, effectively breaking their structure. This lack of
electrostatic interaction increases the size of the NPs (less TPP
interactions to tightly bind the CS polymers together). This
increases the size and intermolecular distance between CS chains
and provides a route for CDDP diffusion out of the NPs. The rate
of release can be modulated by modifying parameters of both the
NP synthesis and postsynthesis conditions. For example, the con-
centration of TPP can be increased to heighten the cross-linking
density of the CDDP NPs and slow the release rate [39]. Addition-
ally, the molecular weight of CS plays a critical role in the release
profile of CS NPs [39]. In vitro testing provides a good model for
CDDP release; however, there are many more variables that exist
in vivo capable of impacting the release profile, such as the pres-
ence of lysozyme which cleaves the b-1,4 glycosidic bonds in
Fig. 5 (a) pH of the CDDP-TPP solution measured at 15 mins
intervals for the initial 2 hrs and at 30 mins intervals over the
course of an additional 5 hrs and (b) rate of the hypothesized
CDDP-TPP reaction. The rate was measured by plotting out the
% decrease in pH over the first hour and analyzing the slopes of
the lines for each condition. We believe that the greater pH
depression rates can be correlated with a more rapid produc-
tion of phosphoric acid.
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between CS monomers [40]. The bolus release profile we
observed is critical for our application of treating oral squamous
cell carcinoma. A large amount of drug released immediately will
destroy cancer cells quickly, reducing the risk of CDDP resistance
developing [33]. Additionally, the release profile of the NPs can
Fig. 6 The percentage cell viability observed when free CDDP, BLK NPs, and CDDP NPs were
incubated with HCPC-1 cells (a) and FaDu cells (b) over the course of 48 hrs at 37 C and 5%
CO2. Both cells lines showed the lowest viability when exposed to the CDDP NPs, followed by
free CDDP and BLK NPs, respectively.
Fig. 7 (a) NP cell uptake microscopy image after 1 hr incubation of OC TR-146
cells with ALX-CS NPs and DAPI stained cell nuclei shown and (b) evaluation of
cell uptake by flow cytometry, percentage of positive cells after 30 and 60 mins
incubation with NPs at a concentration of 0.03 g/L. NPs were taken up by more than
95% of the cells in both cases.
Fig. 8 Release profile of CDDP NPs (2.88:1.00) at pH 7.2 in
PBS. Percentage release was determined using Eqs. (1)–(4)
using Pt concentrations quantified with ICP-AES.
Fig. 9 Photograph of CSM containing CDDP NPs. Note the
smooth surface texture and pure white color. 1.5 cm3 1.5 cm
3 2 mm.
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be controlled by adjusting the pH of the surrounding medium [41]
and cross-linking density. In addition to the in vitro and ex vivo
studies, properties of the CSM were studied in hamster in vivo
experiments. OC tumors were induced in hamsters’ cheek pouch
and CSM were applied topically to the tumor for 1 hr. The details
of these studies are described in the upcoming publications but it
should be noted that CSM showed improved tumor shrinkage over
CDDP injections. Pharmacokinetic studies indicated minor traces
of CDDP in other organs and minimal side effects were observed
in the CSM group. The rapid tumor shrinkage by CSM in ham-
sters further supports the in vitro data of CSM efficacy in destroy-
ing cancer cells while remaining local resulting in safer treatment.
In addition, they indicate that CSM is able to release the CDDP
NPs and the NPs can permeate deep into the tumor. These in vivo
studies have also shown adequate mucoadhesion.
3.5 Synthesis of CSM and SEM. CSMs were successfully
synthesized by the described methods. They were bright white in
color and fluffy in texture (Fig. 9), yet able to be flexed or com-
pressed without breaking. NPs were intact within CSM when
visualized under SEM (Fig. 10(a)) based on the similar textures
observed between isolated lyophilized CDDP NPs and the CSM.
The NP control (lyophilized CDDP NPs, Fig. 10(a)) and CSM
embedded with CDDP NP (Fig. 10(b)) showed multitextured po-
rous surfaces with many physical inconsistencies. In contrast, the
CSM control (lyophilized CS, Fig. 10(c)) displayed a uniform ho-
mogenous texture with no notches or grooves. We postulate that
this texture is present in the NP samples because the CS in that
case is cross-linked, which modifies its natural structure. We pos-
tulate that the degree of porosity and perhaps amount of CS NPs
impacts the release rate and texture of CSM. This porous structure
is critical to its functionality, as an increased number of pores
allows for a high water swelling capacity and rate of NP release.
Contrastingly, the lyophilized CS had a very uniform, tight struc-
ture and virtually no pores, which would inhibit the uptake of
water and rate of NP release.
3.6 Stability of NPs in CSM. It is critical to confirm that af-
ter being subjected to the harsh conditions of being frozen at
196 C and lyophilized for three days, the NPs embedded within
CSM remain both structurally intact and still maintain their func-
tionality. We were able to confirm that viable NPs were released
from CSM into human saliva after being subjected to three days
of lyophilization using NanoSight (Malvern) to quantify the num-
ber and size of NPs (Fig. 11). This method of detection was cho-
sen over DLS because we found that upon dissolving CSM for
DLS measurement, there was background signal created from the
matrix polymers that interfered with NP values. This signal was
not present in NanoSight. We observed an increased size of the
NPs released from the CSM compared to when they were freshly
synthesized (Fig. 11). The measured pH of the human saliva sam-
ple was 7.02 compared to the 3.41 of the NP solution prior to ly-
ophilization. The higher pH caused the CDDP NPs to increase in
size due to the mechanisms previously described. CDDP NPs are
designed to swell in biological conditions to allow for drug
release, thus this experiment confirmed both their integrity and
functionality when embedded with CSM and subsequently
released into a simulated biological environment.
Fig. 10 SEM images of lyophilized free CDDP NPs (a), CDDP NPs embedded within CSM (b), and an image of CS sponge syn-
thesized without any NPs (c). The morphology of the free CDDP NPs and CDDP NPs in CSM are nearly identical, with both
exhibiting a granulated texture. In contrast, the sponge composed of only CS showed a flat, smooth surface texture with no
abnormal structures. This suggests that the NPs remain intact within CSM.
Fig. 11 The concentration and % size increase in FITC NPs
released from CSM in artificial human saliva (pH 7.0) taken
using NanoSight (Malvern). This data confirm the presence of
intact NPs within CSM. The increased size can be attributed to
the higher pH of the saliva compared to the NP synthesis
conditions.
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4 Conclusions
We found that the properties of CS NPs can be modulated by
varying parameters of the synthesis conditions, such as CS con-
centration, TPP concentration, and the pH of CS solution. By con-
trolling these variables, CS NPs can be engineered with a
particular size, charge, and release profile to suit different in vivo
applications. The timely preparation of the CDDP-TPP solution
during NP synthesis is a critical step and should always be used to
prevent any variability between batches due to changing pH.
Some of the key characteristics for success in this application are
stability, integrity of NPs after freezing, and release profile. These
are important because the NPs within CSM must remain intact
and stable throughout the freezing process to ensure the CDDP
remains encapsulated. Additionally, both the release rate of
CDDP from the CS NPs and NPs from CSM play a vital role in its
efficacy.
The ultimate end goal of this paper was to synthesize a trans-
mucosal buccal drug delivery system containing CDDP NPs for
the local, topical treatment of OC. We have developed a poly-
meric CS sponge matrix (CSM) capable of CDDP NPs, which
was confirmed in a series of in vitro experiments. CSMs were
successfully synthesized and tested for their functionality and
presence of NPs, and their structural integrity was verified with
both SEM and NanoSight. This innovation represents a significant
development in the field of oncology, allowing for topical and
local chemotherapy. Our next publication will discuss the in-
depth physical and chemical characterization of CSM as well as
optimization of the CS NP synthesis procedure.
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